<DOC>
	<DOCNO>NCT02621905</DOCNO>
	<brief_summary>The pharmacokinetics Sporanox Lozanoc compare patient require anti-fungal prophylaxis therapy . The present study design compare pharmacokinetics Sporanox Lozanoc patient require primary prophylaxis . The 3-week exposure formulation design allow participant reach steady-state drug , time steady-state vary .</brief_summary>
	<brief_title>Steady-State Comparative Bioavailability Study Prophylaxis Patients Lozanoc® 50 mg With Sporanox® 100 mg</brief_title>
	<detailed_description>After confirmation eligibility , participant randomly assign 1:1 commence therapy either 100mg mane 100mg nocte 21 day Sporanox 200mg mane 200mg nocte food 21 day . If subject enters study already receive itraconazole prophylaxis dose itraconazole high 100 mg twice day , subject dose study pre-study dosage ; , subject take number capsule per day study subject take prior enrolment study . The following information collect baseline ; whether participant take itraconazole prophylaxis dose ; whether participant take gastric suppression therapy . Patients take food take gastric acid suppression therapy ( antacid , H2 antagonist proton pump inhibitor ) take Sporanox cola orange juice maximise absorption recommend Sporanox product label ( require Lozanoc formulation ) . At Day 22 , participant assign - Lozanoc complete 21 day Lozanoc prophylaxis cross number Sporanox capsule food 21 day - Sporanox complete 21 day Sporanox prophylaxis cross number Lozanoc capsule 21 day . The dose either drug may dose-reduced ceased toxicity discretion investigator . During course treatment period participant undergo follow assessment : - Concurrent medication ( ) - Clinical adverse event - Measurement vital sign ( weight , blood pressure , temperature ) - Targeted physical examination - Documentation evidence systemic fungal infection - Medication meal diary - 12-lead electrocardiogram ( ECG ) - Laboratory safety assessment : Renal function electrolyte ( urea , creatinine , estimate glomerular filtration rate [ eGFR ] , sodium , potassium , chloride , bicarbonate ) , Liver function test ( bilirubin , albumin , total protein , alanine aminotransferase [ ALT ] , aspartate aminotransferase [ AST ] ) - Pharmacokinetic testing : Trough ( pre-morning dose ; 0 hr ) sample collect Baseline ( Day 1 ) , Days 8 , 15 , 22 , 29 , 36 43 . Post-dose sample also collect 2 , 3.5 6 hour morning dose Day 22 Day 43</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Provision write , inform consent Age least 18 year No clinical evidence active systemic fungal infection Physicianrecommended primary prophylaxis systemic fungal infection itraconazole patient : heart , lung bone marrow transplant , combination chemotherapy cancer ; aspergilloma , chronic pulmonary aspergillus bronchitis , allergic bronchopulmonary aspergillosis Patients may receive itraconazole prophylaxis prior entry study Body mass index 15.0 35.0 kg/m2 Pregnant , plan pregnancy breastfeed Congestive cardiac failure cause ventricular dysfunction may outweigh benefit itraconazole Hypersensitivity either study drug excipients Coadministration follow drug : CYP3A4 metabolise substrate prolong QTinterval e.g. , sertindole , terfenadine CYP3A4 metabolise HMGCoA reductase inhibitor e.g . simvastatin , lovastatin Potent CYP3A4 inhibitor e.g . dronedarone Triazolam , alprazolam oral midazolam Ergot alkaloid dihydroergotamine , ergometrine ( ergonovine ) ergotamine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Prophylaxis</keyword>
	<keyword>Steady-State</keyword>
	<keyword>Bioavailability</keyword>
</DOC>